Latest & greatest articles for fenofibrate

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on fenofibrate or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on fenofibrate and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for fenofibrate

21. Effects of fenofibrate and gemfibrozil on plasma homocysteine. (Abstract)

Effects of fenofibrate and gemfibrozil on plasma homocysteine. Fenofibrate increases plasma homocysteine. Because the concentration of plasma homocysteine depends on renal function, we postulate that increases in plasma homocysteine are a result of the known impairment of renal function caused by fenofibrate. Gemfibrozil, another fibrate, does not affect renal function. In a crossover study we tested whether gemfibrozil would raise homocysteine. 22 patients who had hypertriglyceridaemia were (...) given 900 mg gemfibrozil or 200 mg fenofibrate daily for 6 weeks. Lipids were altered similarly, but homocysteine, creatinine, and cystatin C were raised by fenofibrate but not by gemfibrozil (p for differences between treatment effects: 0.007, 0.006, and 0.040, respectively). We propose gemfibrozil should be the fibrate of choice.

2001 Lancet Controlled trial quality: uncertain

22. Micronized fenofibrate: a new fibric acid hypolipidemic agent

Micronized fenofibrate: a new fibric acid hypolipidemic agent Micronized fenofibrate: a new fibric acid hypolipidemic agent Micronized fenofibrate: a new fibric acid hypolipidemic agent Guay D R Authors' objectives To assess the efficacy and safety of fenofibrate in the management of hyperlipidaemias. Searching MEDLINE (from 1974 to October 1998) and Currents Contents were searched, and the bibliographies from identified studies were examined. In addition, the package inserts from (...) the manufacturers were used to identify data. Study selection Study designs of evaluations included in the review The inclusion criteria were not defined in terms of study design. The studies included were randomised controlled trials (RCTs) of parallel or crossover design, including double-blinded RCTs, and observational studies. The duration of the comparative studies ranged from 4 weeks to 1 year. Specific interventions included in the review Studies evaluating fenofibrate were eligible. Fenofibrate (regular

1999 DARE.

23. Serum homocysteine increases after therapy with fenofibrate or bezafibrate. (Abstract)

Serum homocysteine increases after therapy with fenofibrate or bezafibrate. A 44% and 17.5% increase of homocysteine occurred in patients treated either with fenofibrate or bezafibrate. The increase was not explained by changes in vitamin concentrations but may be related to renal function.

1999 Lancet Controlled trial quality: uncertain

24. Cost effectiveness of micronised fenofibrate and simvastatin in the short term treatment of type IIa and type IIb hyperlipidaemia

Cost effectiveness of micronised fenofibrate and simvastatin in the short term treatment of type IIa and type IIb hyperlipidaemia Cost effectiveness of micronised fenofibrate and simvastatin in the short term treatment of type IIa and type IIb hyperlipidaemia Cost effectiveness of micronised fenofibrate and simvastatin in the short term treatment of type IIa and type IIb hyperlipidaemia Kirchgassler K U, Schiffner-Rohe J, Stahlheber U Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Micronised Fenofibrate and Simvastatin in the treatment of type IIa and IIb hyperlipidaemia. Type of intervention Treatment; Secondary prevention. Economic study type Cost-effectiveness analysis. Study population Patients (median age 51 years

1997 NHS Economic Evaluation Database.